Rock Springs Capital

Activity in this selectiongoldman-sachs-alternatives-life-sciences-c1335a4c

By stage

Series C+2

Series B1

Biotech3

United States3

3 in this selection

Aug 18

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries D

Role not disclosed

Jun 8

Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas

$99.5MSeries B

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed